The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis
Open accessAbstract
BACKGROUND: As the population that is infected with the hepatitis C virus (HCV) ages, the number of patients with decompensated cirrhosis is expected to increase. METHODS: We conducted a phase 3, open-label study involving both previously treated and previously untreated patients infected with HCV genotypes 1 through 6 who had decompensated cirrhosis (classified as Child-Pugh-Turcotte class B). Patients were randomly assigned in a 1:1:1 ratio to receive the nucleotide polymerase inhibitor sofosbuvir and the NS5A inhibitor velpatasvir once daily for 12 weeks, sofosbuvir-velpatasvir plus ribavirin for 12 weeks, or sofosbuvir-velpatasvir for 24 weeks. The primary end point was a sustained virologic response at 12 weeks after the end of therapy. RESULTS: Of the 267 patients who received treatment, 78% had HCV genotype 1, 4% genotype 2, 15% genotype 3, 3% genotype 4, and less than 1% genotype 6; no patients had genotype 5. Overall rates of sustained virologic response were 83% (95% confidence interval [CI], 74 to 90) among patients who received 12 weeks of sofosbuvir-velpatasvir, 94% (95% CI, 87 to 98) among those who received 12 weeks of sofosbuvir-velpatasvir plus ribavirin, and 86% (95% CI, 77 to 92) among those who received 24 weeks of sofosbuvir-velpatasvir. Post hoc analysis did not detect any significant differences in rates of sustained virologic response among the three study groups. Serious adverse events occurred in 19% of patients who received 12 weeks of sofosbuvir-velpatasvir, 16% of those who received 12 weeks of sofosbuvir-velpatasvir plus ribavirin, and 18% of those who received 24 weeks of sofosbuvir-velpatasvir. The most common adverse events were fatigue (29%), nausea (23%), and headache (22%) in all patients and anemia (31%) in the patients receiving ribavirin. CONCLUSIONS: Treatment with sofosbuvir-velpatasvir with or without ribavirin for 12 weeks and with sofosbuvir-velpatasvir for 24 weeks resulted in high rates of sustained virologic response in patients with HCV infection and decompensated cirrhosis. (Funded by Gilead Sciences; ASTRAL-4 ClinicalTrials.gov number, NCT02201901.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection
Feld, J. J., Jacobson, I. M., Hézode, C., Asselah, T., Ruane, P. J., Gruener, N., Abergel, A., Mangia, A., Lai, C.-L., Chan, H. L. Y., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1512610 · Cited by 1,106
Self-citationDavis, G. L., Alter, M. J., El–Serag, H., Poynard, T., & Jennings, L. W. (2010) · Gastroenterology · doi:10.1053/j.gastro.2009.09.067 · Cited by 878
Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection
Foster, G. R., Afdhal, N., Roberts, S. K., Bräu, N., Gane, E. J., Pianko, S., Lawitz, E., Thompson, A., Shiffman, M. L., Cooper, C., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1512612 · Cited by 846
Self-citationCharlton, M., Everson, G. T., Flamm, S. L., Kumar, P., Landis, C., Brown, R. S., Fried, M. W., Terrault, N. A., O'Leary, J. G., Vargas, H. E., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.05.010 · Cited by 802
Self-citationForns, X., Charlton, M., Denning, J., McHutchison, J. G., Symonds, W. T., Brainard, D., Brandt‐Sarif, T., Chang, P., Kivett, V., Castells, L., et al. (2015) · Hepatology · doi:10.1002/hep.27681 · Cited by 229
Self-citationDeterding, K., zu Siederdissen, C. H., Port, K., Solbach, P., Sollik, L., Kirschner, J., Mix, C., Cornberg, J., Worzala, D., Mix, H., et al. (2015) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13343 · Cited by 127
Everson, G. T., Towner, W. J., Davis, M. N., Wyles, D. L., Nahass, R., Thuluvath, P. J., Etzkorn, K., Hinestrosa, F., Tong, M. J., Rabinovitz, M., et al. (2015) · Annals of Internal Medicine · doi:10.7326/m15-1000 · Cited by 111
Self-citationSaxena, V., Nyberg, L. M., Pauly, M. P., Dasgupta, A., Nyberg, A. H., Piasecki, B. A., Winston, B. J., Redd, J. L., Ready, J. B., & Terrault, N. A. (2015) · Hepatology · doi:10.1002/hep.27922 · Cited by 110
Poordad, F. F., Schiff, E. R., Vierling, J. M., Landis, C. S., Fontana, R. J., Yang, R., McPhee, F., Hughes, E., Noviello, S., & Swenson, E. S. (2015) · Journal of Hepatology · doi:10.1016/s0168-8278(15)30154-9 · Cited by 99
Self-citationLiver toxicity associated with sofosbuvir, an NS5A inhibitor and ribavirin use
Dyson, J. K., Hutchinson, J., Harrison, L. E. A., Rotimi, O., TINIAKOS, D. G., Foster, G. R., Aldersley, M. A., & McPherson, S. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.07.041 · Cited by 96
Cited by
EASL Recommendations on Treatment of Hepatitis C 2018
Pawlotsky, J.-M., Negro, F., Aghemo, A., Berenguer, M., Dalgard, O., Dusheiko, G., Marra, F., Puoti, M., & Wedemeyer, H. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.03.026 · Cited by 2,827
Approved Antiviral Drugs over the Past 50 Years
De Clercq, E., & Li, G. (2016) · Clinical Microbiology Reviews · doi:10.1128/cmr.00102-15 · Cited by 1,430
EASL recommendations on treatment of hepatitis C: Final update of the series☆
Pawlotsky, J.-M., Negro, F., Aghemo, A., Berenguer, M., Dalgard, O., Dusheiko, G., Marra, F., Puoti, M., & Wedemeyer, H. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.08.018 · Cited by 1,252
Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection
Feld, J. J., Jacobson, I. M., Hézode, C., Asselah, T., Ruane, P. J., Gruener, N., Abergel, A., Mangia, A., Lai, C.-L., Chan, H. L. Y., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1512610 · Cited by 1,106
Self-citationEASL Recommendations on Treatment of Hepatitis C 2016
(2017) · Journal of Hepatology · doi:10.1016/j.jhep.2016.09.001 · Cited by 985
Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection
Foster, G. R., Afdhal, N., Roberts, S. K., Bräu, N., Gane, E. J., Pianko, S., Lawitz, E., Thompson, A., Shiffman, M. L., Cooper, C., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1512612 · Cited by 846
Self-citationPanel, A.-I. H. G., Chung, R. T., Ghany, M. G., Kim, A. Y., Marks, K. M., Naggie, S., Vargas, H. E., Aronsohn, A. I., Bhattacharya, D., Broder, T., et al. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/ciy585 · Cited by 717
Self-citationOral Direct-Acting Agent Therapy for Hepatitis C Virus Infection: A Systematic Review
Falade-Nwulia, O., Suarez-Cuervo, C., Nelson, D. R., Fried, M. W., Segal, J. B., & Sulkowski, M. S. (2017) · Annals of Internal Medicine · doi:10.7326/m16-2575 · Cited by 688
Self-citationGoldberg, D., Ditah, I. C., Saeian, K., Lalehzari, M., Aronsohn, A., Gorospe, E. C., & Charlton, M. (2017) · Gastroenterology · doi:10.1053/j.gastro.2017.01.003 · Cited by 604
Self-citationHepatitis C Virus Resistance to Direct-Acting Antiviral Drugs in Interferon-Free Regimens
Pawlotsky, J.-M. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.04.003 · Cited by 519
Manns, M. P., Buti, M., Gane, E., Pawlotsky, J.-M., Razavi, H., Terrault, N., & Younossi, Z. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.6 · Cited by 506
Foster, G. R., Irving, W. L., Cheung, M. C. M., Walker, A. J., Hudson, B. E., Verma, S., McLauchlan, J., Mutimer, D. J., Brown, A., Gelson, W. T. H., et al. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.01.029 · Cited by 492
Poordad, F., Schiff, E. R., Vierling, J. M., Landis, C., Fontana, R. J., Yang, R., McPhee, F., Hughes, E. A., Noviello, S., & Swenson, E. S. (2016) · Hepatology · doi:10.1002/hep.28446 · Cited by 460
Self-citationUse of Liver Imaging and Biopsy in Clinical Practice
Tapper, E. B., & Lok, A. S.-F. (2017) · New England Journal of Medicine · doi:10.1056/nejmra1610570 · Cited by 442
Cheung, M. C. M., Walker, A. J., Hudson, B. E., Verma, S., McLauchlan, J., Mutimer, D. J., Brown, A., Gelson, W. T. H., MacDonald, D. C., Agarwal, K., et al. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.06.019 · Cited by 408
Belli, L. S., Perricone, G., Adam, R., Cortesi, P. A., Strazzabosco, M., Facchetti, R., Karam, V., Salizzoni, M., Andujar, R. L., Fondevila, C., et al. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.06.010 · Cited by 251
Acute Rejection Increases Risk of Graft Failure and Death in Recent Liver Transplant Recipients
Levitsky, J., Goldberg, D., Smith, A. R., Mansfield, S. A., Gillespie, B. W., Merion, R. M., Lok, A. S. F., Levy, G., Kulik, L., Abecassis, M., et al. (2017) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2016.07.035 · Cited by 236
Watanabe, Y., Tsuchiya, A., Seino, S., Kawata, Y., Kojima, Y., Ikarashi, S., Starkey Lewis, P. J., Lu, W.-Y., Kikuta, J., Kawai, H., et al. (2019) · Stem Cells Translational Medicine · doi:10.1002/sctm.18-0105 · Cited by 155
Kojima, Y., Tsuchiya, A., Ogawa, M., Nojiri, S., Takeuchi, S., Watanabe, T., Nakajima, K., Hara, Y., Yamashita, J., Kikuta, J., et al. (2019) · Regenerative Therapy · doi:10.1016/j.reth.2019.08.005 · Cited by 43
Hepatic decompensation during direct-acting antiviral therapy of chronic hepatitis C
Hoofnagle, J. H. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.01.007 · Cited by 31
Chen, B., Pang, L., Cao, H., Wu, D., Wang, Y., Tao, Y., Wang, M., & Chen, E. (2019) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000001455 · Cited by 14
Ishikawa, N., Watanabe, Y., Maeda, Y., Yoshida, T., Kimura, N., Abe, H., Sakamaki, A., Kamimura, H., Yokoo, T., Kamimura, K., et al. (2025) · Regenerative Therapy · doi:10.1016/j.reth.2025.01.017 · Cited by 6
Metadata
- Authors
- Curry, M. P., O’Leary, J. G., Bzowej, N., Muir, A. J., Korenblat, K. M., Fenkel, J. M., Reddy, K. R., Lawitz, E., Flamm, S. L., Schiano, T., Teperman, L., Fontana, R., Schiff, E., Fried, M., Doehle, B., An, D., McNally, J., Osinusi, A., Brainard, D. M., McHutchison, J. G., Brown, R. S., & Charlton, M.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-12-31
- Volume
- 373
- Issue
- 27
- Pages
- 2618-2628
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2266909385
- Cited by
- 804
- References
- 11
- FWCI
- 66.18
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.